Hal Crow, Chairman
New Solutions for Oncology
Tosk is on a mission to improve outcomes for cancer patients worldwide through the development of low-cost small molecule drugs designed to eliminate the adverse side effects associated with chemotherapeutics and radiation.
*For Accredited Investors Only
About Us
"We develop transformative, cost-effective therapies for cancer that will serve a worldwide market."
- Clinical Stage, Small Molecule Drug Discovery, and Development Company
- Addressing Large, Unmet Medical Needs, >50% of All Cancers
- Experienced Management Team, Big Pharma, Multiple Startup Exits
- $27 Million Funding to Date
Investor Brief
- Reg D Offerings (Regulations Definitions)
- Minimum Investment: $250,000
- Company Raise: $10,000,000